Neurogene reports Q2 net loss $22M; cash $274.5M, FDA agrees on registrational trial design for Rett gene therapy

Neurogene Inc.

2025-Q2 EPS reported -$2.12 vs consensus -$1.18 ▼ miss (-79.4%)

Net loss of $22.0M for Q2 2025 vs $18.5M in Q2 2024; R&D expenses $19.4M vs $15.7M.
Cash, cash equivalents and short-term investments $274.5M as of June 30, 2025; runway into early 2028.
FDA provided written agreement on key elements of Embolden registrational trial for NGN-401; sample size refined to propose 20 participants.
Completed dosing in Phase 1/2 NGN-401 trial; last 5 participants dosed in H1 2025; updated clinical data expected H2 2025.
No evidence of HLH/hyperinflammatory syndrome in any NGN-401 participant at 1E15 vg dose level as of press date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.